Dr. Lawrence A. Yannuzzi, Md

Name	:	Dr. Lawrence A. Yannuzzi, MD
Website	:	Visit Website
Blog	:	Visit Blog
Social Links	:

About Dr. Lawrence A. Yannuzzi, Md

Dr. Yannuzzi is founder of VRMNY as well as vice-chairman and director of the LuEsther T. Mertz Retinal Research Center of the Manhattan Eye, Ear & Throat Hospital. He is also founder and president of The Macula Foundation, Inc., which has distributed several million dollars to eye research across the country. Dr. Yannuzzi has made numerous innovative and lasting contributions in imaging, drug development, and therapeutic modalities. He was the first to use oral non-steroid anti-inflammatory medication for the treatment of cystoid macular edema and developed an eye drop to treat this condition. He has described new diseases as well as new associations and manifestations of established entities and photosensitization.

Advantages of Services in Vitreous Retina Macula Consultants of New York

Dr. Lawrence A. Yannuzzi, Md23 Apr, 2024Health

The ophthalmologists and retina specialists at Vitreous Retina Macula Consultants of New York are internationally known leaders in diagnosing and treating retinal diseases. VRMNY retina doctors have trained and taught at some of the world's finest and most respected academic institutions. The physicians who comprise the best retina specialists in New York are experts in vitrectomy surgery and hold academic appointments at Lenox Hill Hospital, New York University, and the New York Eye and Ear Infirmary. Our ophthalmologists in New York City specialize in treating all medical and surgical retinal conditions, emphasizing macular degeneration and diabetic retinopathy, the two leading causes of retinal vision loss.

Macular Hole Treatment in New York, NY

Dr. Lawrence A. Yannuzzi, Md23 Apr, 2024Health

The macula is the very small area in the back of the retina that is responsible for providing sharpness and clarity in our vision. This detailed vision is necessary for daily tasks such as reading, driving, and watching television. A jelly-like substance called the vitreous fills the central portion of the eye. It is composed of 99% water, some chemicals to create the gel, and long protein fibers. As we age the vitreous begins to shrink. The jelly starts to break down and the protein fibers start to aggregate. In most people the vitreous eventually separates from the retina in a process called posterior vitreous detachment.

Diabetic Retinopathy Treatment in New York, NY

Dr. Lawrence A. Yannuzzi, Md23 Apr, 2024Health

People with diabetes are unfortunately at a higher risk for numerous ocular complications, which can lead to severe vision loss and sometimes even blindness. One of those eye diseases is diabetic retinopathy, the leading cause of blindness among Americans. Diabetic retinopathy is an eye disease that damages the blood vessels in the retina. While what exactly causes this damage is not known, poorly controlled blood sugar levels are believed to be a contributing factor. Although diabetic retinopathy can affect persons with Type I or Type II diabetes, persons with Type I diabetes are at a greater risk of developing the disease. Over time, the risk of developing diabetic retinopathy increases.

Macular Degeneration Treatment in New York, NY

Dr. Lawrence A. Yannuzzi, Md23 Apr, 2024Health

Many people with macular degeneration experience minimal vision loss during the early stages of the disease. For most people, macular degeneration does not become vision impairing. During this stage, the transport of wastes and nutrients by the RPE has slowed down. As a result, waste builds up under the retina and forms yellowish deposits known as drusen. An ophthalmologist examining a patient at this stage may see drusen, although no symptoms may be present or develop later. If the doctor sees drusen, the patient will be monitored. In most cases, the disease will not progress to vision loss, although some patients do experience vision loss with drusen. Many patients over 60 have some drusen.